Uridine Diphosphate Glucuronosyltransferase
Uridine Diphosphate Glucuronosyltransferase - Related Videos
01:27
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
0 Views •
2026
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
04:00
Spectrophotometric Assay to Determine Glycogen Synthase Activity
0 Views •
2025
This video describes a spectrophotometric assay for the estimation of glycogen synthase activity. The method relies on the reduction in the absorbance of NADH with time and indicates glycogen synthase activity.
01:08
Hydrolysis of ATP
0 Views •
2019
The bonds of adenosine triphosphate (ATP) can be broken through the addition of water, releasing one or two phosphate groups in an exergonic process called hydrolysis. This reaction liberates the energy in the bonds for use in the cell—for instance, to synthesize proteins from amino acids. If one phosphate group is removed, a molecule of ADP—adenosine diphosphate—remains, along with inorganic phosphate. ADP can be further hydrolyzed to AMP—adenosine monophosphate—by the removal of a second...
05:07
An In Vitro Method for the Differentiation of Megakaryocytes and Platelet Formation
0 Views •
2025
This video demonstrates a technique for the differentiation of megakaryocytes and the formation of platelets. Hematopoietic stem progenitor cells — isolated from human umbilical cord blood — differentiate into mature megakaryocytes in the presence of thrombopoietin. The mature megakaryocytes produce cytoplasmic extensions termed proplatelets, which give rise to individual platelets.
15:22
Nucleoside Triphosphates - From Synthesis to Biochemical Characterization
0 Views •
Cited by 4 •
2014
The protocol described herein aims to explain and abridge the numerous obstacles in the way of the intricate route leading to modified nucleoside triphosphates. Consequently, this protocol facilitates both the synthesis of these activated building-blocks and their availability for practical applications.
FAQs
UGT enzymes use UDP-glucuronic acid as the source of glucuronic acid during conjugation. Adding this group changes the properties of the target compound, generally increasing its water solubility. That chemical change helps the body handle bilirubin, medications, hormones, and other substrates through subsequent elimination, making the donor molecule central to the reaction.
Individual UGT enzymes act on specific substrates rather than treating every compound identically. This selectivity helps explain why variation in one enzyme can affect bilirubin, a medication, or a hormone without producing identical effects on all compounds. Clinically, identifying the relevant substrate-enzyme relationship supports more focused interpretation of metabolism and clearance.
When UGT activity is reduced, the affected substrate may be cleared less efficiently. For bilirubin, this can contribute to unconjugated hyperbilirubinemia. For drugs, altered activity can change clearance and therefore influence medication exposure. The clinical consequence depends on which substrate is involved and how strongly its metabolism depends on the affected enzyme.
UGT1A1 is clinically important because inherited disorders involving this enzyme can impair bilirubin handling and contribute to unconjugated hyperbilirubinemia. Its relevance also illustrates how a specific member of the UGT family can connect molecular variation with a recognizable clinical finding, supporting targeted evaluation when bilirubin abnormalities suggest an inherited metabolic disorder.
Pharmacogenomic testing can help evaluate whether genetic variation may account for altered UGT activity and drug clearance. It is most relevant when clinicians need to connect a medication response or metabolism concern with inherited differences in enzyme function. Results add genetic context to medication safety decisions but must be interpreted alongside the clinical situation.
UGT knowledge supports two related clinical applications: assessing whether genetic differences could alter medication clearance and investigating inherited conditions associated with reduced enzyme activity. In practice, clinicians can use the relationship among the substrate, the relevant UGT enzyme, and the observed finding to guide interpretation of drug metabolism concerns or unconjugated hyperbilirubinemia.